Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754566 | 0.83 | SIGMAR1 (0.45) | SIGMAR1TMEM97ABCB1GRIN1GRIN2B | |
| SCHEMBL25754561 | 0.82 | SIGMAR1 (0.41) | SIGMAR1TMEM97ABCB1GRIN1GRIN2B | |
| SCHEMBL25754653 | 0.78 | HRH3 (0.45) | SIGMAR1SMN1; SMN2CYP1A2 | |
| SCHEMBL25754671 | 0.75 | HRH3 (0.38) | SIGMAR1TMEM97 | |
| SCHEMBL17404456 | 0.74 | SIGMAR1 (0.45) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL6656817 | 0.74 | SIGMAR1 (0.57) | SIGMAR1TMEM97ABCB1GRIN1GRIN2B | |
| SCHEMBL6659238 | 0.74 | SIGMAR1 (0.61) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL25754661 | 0.72 | HRH3 (0.40) | SIGMAR1TMEM97 | |
| SCHEMBL25754655 | 0.72 | HRH3 (0.45) | SIGMAR1SMN1; SMN2CYP1A2 | |
| SCHEMBL6660619 | 0.72 | SIGMAR1 (0.56) | SIGMAR1TMEM97ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | SIGMAR1 4773/4885TMEM97 4183/4885SMN1; SMN2 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.